Subtyping of triple‐negative breast cancer: Implications for therapy
Top Cited Papers
Open Access
- 16 July 2014
- Vol. 121 (1), 8-16
- https://doi.org/10.1002/cncr.28914
Abstract
Triple‐negative breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified 6 distinct TNBC subtypes, each of which displays a unique biology. Exploring novel approaches for the treatment of these subtypes is critical, especially because the median survival for women with metastatic TNBC is less than 12 months, and virtually all women with metastatic TNBC ultimately will die of their disease despite systemic therapy. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard treatment. In this review, the authors discuss recent developments in subtyping TNBC and the current and upcoming therapeutic strategies being explored in an attempt to target TNBC. Cancer 2015;121:8–16. © 2014 American Cancer Society.Keywords
Funding Information
- NIH (CA95131)
This publication has 47 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNature Medicine, 2011
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerThe New England Journal of Medicine, 2011
- Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy responseBreast Cancer Research and Treatment, 2009
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K SignalingCancer Cell, 2009
- Most Basal-like Breast Carcinomas Demonstrate the Same Rb−/p16+ Immunophenotype as the HPV-related Poorly Differentiated Squamous Cell Carcinomas Which They Resemble MorphologicallyThe American Journal of Surgical Pathology, 2009
- How basal are triple‐negative breast cancers?International Journal of Cancer, 2008
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative PhenotypeClinical Cancer Research, 2008
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004